FORMODUAL

Informació principal

  • Denominació comercial:
  • FORMODUAL 100/6 mcg aerosol 120 dosis
  • formulario farmacéutico:
  • Aerosol
  • Vía de administración:
  • Inhalatoria
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • FORMODUAL 100/6 mcg aerosol 120 dosis
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 659075
  • última actualització:
  • 09-06-2018

Prospecte: composició, indicacions, interacció, posologia, embaràs, lactància, reaccions adverses

FORMODUAL 100/6 mcg aerosol 120 dosis

formoterol+beclometasona

Indicacions

Medicament que relaxa i disminueix la inflamaci

de les vies respirat

ries i alleuja la dificultat per

respirar produ

da per l'asma i altres malalties respirat

ries (ANTIASM

TIC).

Consideracions

NO s'administri aquest medicament si

s al

rgic a CORTICOIDES.

Expulsi la major quantitat d'aire dels pulmons; inhali el medicament i retingui l'aire inspirat durant uns

segons. Despr

s expulsi l'aire lentament.

Si necessita realitzar diverses inhalacions, esperi 1 minut entre l'una i l'altra.

Netegi amb aigua t

bia i assequi la part del dispositiu que entra en contacte amb la boca despr

s de

cada aplicaci

Esbandeixi's la boca amb aigua despr

s d'haver inhalat la dosi indicada.

Aquest medicament triga algun temps a fer efecte, NO deixi d'aplicar-se'l encara que al principi no noti

millora.

Tot i notar milloria, NO deixi d'aplicar-se aquest medicament durant el temps indicat pel seu metge.

Si vost

nota que disminueix l'efic

cia del medicament, NO augmenti la dosi sense consultar-ho

abans amb el seu metge.

NO utilitzi aquest medicament a l'atac agut d'asma.

Avisi el seu metge si pateix o ha patit problemes de cor, problemes de fetge o problemes de tiroides.

Si vost

猫 茅

s diab

tic/a, tingui en compte que aquest medicament pot alterar els nivells de glucosa en

sang i orina.

Informi immediatament el seu metge si est

embarassada o creu que pot estar-ho, aix

com si qued

s embarassada durant el tractament.

Avisi al seu metge si t

algun fill a qui estigui alletant.

Efectes adversos

Avisi el seu metge si durant el tractament apareix dolor o taques blanques a la boca i a la gola.

Aquest medicament pot produir sabor amarg, ronquera i sequetat de boca.

Si not

s qualsevol altre s

mptoma que creu que pot ser causat per aquest medicament, digui-li-ho al

seu metge.

Posologia

Realitzi 2 inhalacions cada 12 hores.

VIA INHALAT

RIA.

10-4-2019

DuoResp Spiromax (Teva Pharma B.V.)

DuoResp Spiromax (Teva Pharma B.V.)

DuoResp Spiromax (Active substance: budesonide / formoterol) - Centralised - Renewal - Commission Decision (2019)2810 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/002348/R/0027

Europe -DG Health and Food Safety

10-4-2019

BiResp Spiromax (Teva Pharma B.V.)

BiResp Spiromax (Teva Pharma B.V.)

BiResp Spiromax (Active substance: budesonide / formoterol) - Centralised - Renewal - Commission Decision (2019)2811 of Wed, 10 Apr 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/003890/R/0027

Europe -DG Health and Food Safety

1-3-2019


Summary of opinion: Trydonis,beclometasone / formoterol / glycopyrronium bromide,  28/02/2019,  Positive

Summary of opinion: Trydonis,beclometasone / formoterol / glycopyrronium bromide, 28/02/2019, Positive

Summary of opinion: Trydonis,beclometasone / formoterol / glycopyrronium bromide, 28/02/2019, Positive

Europe - EMA - European Medicines Agency

1-3-2019


Summary of opinion: Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),beclometasone / formoterol / glycopyrronium bromide,  28/02/2019,  Positive

Summary of opinion: Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),beclometasone / formoterol / glycopyrronium bromide, 28/02/2019, Positive

Summary of opinion: Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),beclometasone / formoterol / glycopyrronium bromide, 28/02/2019, Positive

Europe - EMA - European Medicines Agency

5-2-2019


Human medicines European public assessment report (EPAR): Bevespi Aerosphere, glycopyrronium / formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 18/12/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Bevespi Aerosphere, glycopyrronium / formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 18/12/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Bevespi Aerosphere, glycopyrronium / formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 18/12/2018, Status: Authorised

Europe - EMA - European Medicines Agency

25-1-2019

Trimbow (Chiesi Farmaceutici S.p.A.)

Trimbow (Chiesi Farmaceutici S.p.A.)

Trimbow (Active substance: beclometasone / formoterol / glycopyrronium bromide) - Centralised - 2-Monthly update - Commission Decision (2019)686 of Fri, 25 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4257/II/02

Europe -DG Health and Food Safety

20-12-2018

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (Active substance: glycopyrronium bromide / formoterol) - New authorisation - Commission Decision (2018)9127 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4245

Europe -DG Health and Food Safety

14-12-2018


Summary of opinion: Trimbow,beclometasone / formoterol / glycopyrronium bromide,  13/12/2018,  Positive

Summary of opinion: Trimbow,beclometasone / formoterol / glycopyrronium bromide, 13/12/2018, Positive

Summary of opinion: Trimbow,beclometasone / formoterol / glycopyrronium bromide, 13/12/2018, Positive

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate, decision type: , therapeutic area: , PIP number: P/0159/2018

Europe - EMA - European Medicines Agency

7-8-2018

Duaklir Genuair (AstraZeneca AB)

Duaklir Genuair (AstraZeneca AB)

Duaklir Genuair (Active substance: aclidinium bromide / formoterol fumarate dihydrate) - Centralised - Yearly update - Commission Decision (2018)5419 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

7-8-2018

Brimica Genuair (AstraZeneca AB)

Brimica Genuair (AstraZeneca AB)

Brimica Genuair (Active substance: aclidinium bromide / formoterol fumarate dihydrate) - Centralised - Yearly update - Commission Decision (2018)5420 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

2-5-2018

Trydonis (Chiesi Farmaceutici S.p.A.)

Trydonis (Chiesi Farmaceutici S.p.A.)

Trydonis (Active substance: beclometasone / formoterol / glycopyrronium bromide) - Centralised - Authorisation - Commission Decision (2018)2713 of Wed, 02 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4702

Europe -DG Health and Food Safety

26-4-2018

Riarify (Chiesi Farmaceutici S.p.A.)

Riarify (Chiesi Farmaceutici S.p.A.)

Riarify (Active substance: beclometasone / formoterol / glycopyrronium bromide) - New authorisation - Commission Decision (2018)2581 of Thu, 26 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4836

Europe -DG Health and Food Safety